How effective is Ryeqo (Relugolix compound tablets)?

(Relugolix compound tablets) is a non-peptide small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. As the first oral GnRH antagonist, it can bind to and block the GnRH receptor in the anterior pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing the production of estrogen and progesterone in the female ovary. This product also reduces the production of testosterone in men, so it has a good therapeutic effect on hormone-dependent diseases.

A 24-week phase II trial to evaluate the safety of 10 mg, 20 mg, 40 mg Ryeqo, placebo, and leuprolide in premenopausal patients with endometriosis (EMs)-related pain. The results showed that Ryeqo was well tolerated during the 24-week treatment period and was as effective as leuprolide in treating EMs-related pelvic pain. The estrogen levels in each Ryeqo group decreased, which was positively related to the dose. Among them, the estrogen levels in the 40 mg group were lower than postmenopausal levels within 24 weeks. Bone mass loss was observed in all groups, was positively correlated with dose, and was comparable to leuprolide in the 40 mg group.

Among the findings found in the experiment are increased sweating, lumps in the breast tissue (breast cysts), hair loss, decreased interest in sex, irritability, indigestion, night sweats, hot flashes, excessive, irregular or persistent bleeding from the uterus (uterine bleeding), and more. Finally, the editor of Medical Companion Travel would like to remind patients who are currently using Ryeqo that only by carefully following the doctor's instructions can the effect of the drug itself be maximized.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.